Category Archives: Cell and Gene Therapy (CGT)

Considerations for Early-Phase Clinical Trial Design for Cell and Gene Therapy Products

Considerations for Early-Phase Clinical Trial Design for Cell and Gene Therapy Products By Michelle Villasmil, Ph.D., Scientist at Cato Research Despite the potential benefits of cell and gene therapy (CGT), early experiences with some CGT products have presented considerable risks … Continue reading

Posted in Cato Research, Cell and Gene Therapy (CGT), Clinical Trials, FDA, Regulatory Strategy | Tagged , , , | Comments Off on Considerations for Early-Phase Clinical Trial Design for Cell and Gene Therapy Products